Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) reported 6/30/2017 earnings this Morning, coming in at ($0.42) per share, missing Wall Street’s estimates of ($0.41) per Share. Revenue for the quarter came in at $27.62 million beating analyst estimates of $21.37 million
Analyst Coverage For Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)
These are 3 Buy Ratings .
The current consensus rating for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) is Buy (Score: 3.00) with a consensus target price of $8.75 , a potential (667.54% upside)Recent Insider Trading for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)
- On 7/28/2017 Scott J Charles, CFO, sold 10,804 with an average share price of $1.25 per share and the total transaction amounting to $13,505.00.
- On 6/23/2017 Eric Trachtenberg, Insider, sold 7,720 with an average share price of $1.33 per share and the total transaction amounting to $10,267.60.
- On 6/15/2017 Arthur S Kirsch, Director, bought 15,000 with an average share price of $1.15 per share and the total transaction amounting to $17,250.00.
- On 6/14/2017 Arthur S Kirsch, Director, bought 50,000 with an average share price of $1.17 per share and the total transaction amounting to $58,500.00.
- On 6/5/2017 Andrew I Koven, Insider, sold 161,906 with an average share price of $1.28 per share and the total transaction amounting to $207,239.68.
- On 5/23/2017 Jason Aryeh, Director, sold 388,685 with an average share price of $1.44 per share and the total transaction amounting to $559,706.40.
Dividend History for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)
- On 11/21/2013 announced a special dividend of $1.75 with an ex dividend date of 12/31/2013 which will be payable on 12/11/2013.
Recent Trading for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Shares of Aralez Pharmaceuticals Inc. closed the previous trading session at 1.18 up +0.04 3.51% with 937,430 shares trading hands.